Numerous options are currently available for tumour typing. This has raised intense interest
in the elucidation of prognostic and predictive markers. A prognostic biomarker provides …

Cetuximab and panitumumab, as the highly effective antibodies targeting epidermal growth
factor receptor (EGFR), have clinical activity in the patients with metastatic colorectal cancer …

Rapidly growing insights into the molecular biology of colorectal cancer (CRC) and recent
developments in gene sequencing and molecular diagnostics have led to high expectations …

KRAS and BRAF mutations lead to the constitutive activation of EGFR signaling through the
oncogenic Ras/Raf/Mek/Erk pathway. Currently, KRAS is the only potential biomarker for …

Abstract Gefitinib (Iressa, ZD-1839), a small molecule tyrosine kinase inhibitor (TKI) of the
epidermal growth factor receptor (EGFR) pathway, is currently under investigation in clinical …

KRAS and BRAF mutations predict the resistance of colorectal carcinomas to therapy
targeted to the epidermal growth factor receptor, but their detection can be challenging …

Emergence of novel treatment modalities provides effective therapeutic options, apart from
conventional cytotoxic chemotherapy, to fight against colorectal cancer. Unfortunately, drug …

In the US, colorectal cancer is the third leading cause of cancer-related death.
Approximately 20% of patients present with metastatic disease, and an additional 30% to …

The treatment of metastatic colorectal cancer (mCRC) has become increasingly complex
and nuanced as treatments have evolved over the last decade. During that time, treatment …

The incidence of oral cancer remains high in both Asian and Western countries. Several risk
factors associated with development of oral cancer are now well-known, including tobacco …